Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Genotyping cell-free DNA in lung cancer patients

Official title: Molecular Analysis of the Surnantant of Echoguidated Bronchoscopic Cytopunctions in Lung Cancer

Run by University Hospital, Toulouse · NCT04624373 · Data updated 2026-11-12

This study is testing a less invasive way to check for specific gene changes in lung cancer patients using a blood sample to help doctors make better treatment decisions.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment50 (estimated)
SponsorUniversity Hospital, Toulouse
Academic / other
Locations1 site (Toulouse)
StatusRecruiting
StartedApril 1, 2021
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedApril 3, 2025
Trial IDNCT04624373 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old who are scheduled for an EBUS-TBNA due to suspected stage IV lung cancer or have stage IV NSCLC with specific mutations and resistance to targeted therapies.

Probably not a fit

Patients who refuse to participate or are under legal tutelage will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the genotyping of cell-free DNA obtained from the supernatant of EBUS-TBNA procedures in patients with non-small cell lung cancer (NSCLC). It aims to improve the accuracy of tumor genotyping by utilizing liquid biopsy techniques, which are less invasive than traditional tissue biopsies. The study addresses the challenge of limited tissue availability for multiplex analysis of various targetable mutations and markers, particularly in patients with advanced disease. By analyzing the molecular profile of tumors through minimally invasive methods, the study seeks to enhance treatment decision-making for lung cancer patients.

Why it matters

Potential benefit: If successful, this approach could lead to more accurate and timely identification of actionable mutations in lung cancer patients, improving treatment outcomes.

How similar studies have gone: Other studies have shown promise in using liquid biopsy techniques for genotyping in cancer, indicating that this approach is gaining traction in the field.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18 years-old
* Patients planned for an EBUS-TBNA for

  1. Suspicion of stage IV lung cancer (PET+ mediastinal node(s)) (Cohort 1)
  2. Stage IV NSCLC with an EGFR, BRAF, HER2, MET mutation or ALK, RET or ROS1 rearranged NSCLC and acquired resistance to targeted therapy (Cohort 2)
* Performance status 0-3
* Informed consent

Exclusion Criteria:

* Refusal to participate
* Patient under legal tutelage

Where it's running

  • Nicolas Guibert
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.